A molecular diagnostics company, which develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets
Cepheid was founded in March 1996, by Thomas Gutshall, Bill McMillan, Dr. Kurt Petersen, Dr. Greg Kovacs, Steven Young and Dr. Allen Northrup.
The company’s first CEO was Tom Gutshall, who held the position from 1996 to 2002. In April 2002, John Bishop was appointed CEO.
The initial public offering was June 21, 2000, at $6 per share. Cepheid stock is traded on the Nasdaq Global Market System under the ticker symbol CPHD.
Cepheid is on the forefront and arguably the leader in Molecular Diagnostics Testing which advances health in our communities
Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with their first system and they’ve never looked back. And now, even with the largest installed base of any molecular platform, Cepheid is constantly innovating and evolving our capabilities. Their technology has been heralded as game-changing by healthcare leaders world-wide. They envision a better way for clinical institutions of any size, from small medical clinics to high-volume reference laboratories and major hospitals, to access the power of molecular diagnostics. Their GeneXpert® System delivers fast, scalable, and accurate diagnostic results while their expanding Xpert® test menu spans multiple clinical applications such as healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology.
Cepheid offers a GeneXpert system for testing in the areas of healthcare-associated infections, critical infectious disease, sexual health, virology, oncology, and genetics. It also provides a SmartCycler system, which integrates DNA amplification and detection to allow analysis of a sample; and Xpert tests for use on the GeneXpert system.
The company sells its products through its direct sales force and distributors worldwide. It has collaboration arrangements with Life Technologies Corporation to develop reagents for use in the USPS BDS program; Foundation for Innovative New Diagnostics to develop tests that can detect mycobacterium tuberculosis and associated rifampin resistance from human sputum samples; and Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert Ebola, an Ebola test to be run on its GeneXpert Systems. The company was incorporated in 1996 and is headquartered in Sunnyvale, California. As of November 4, 2016, Cepheid operates as a subsidiary of Danaher Corporation.
Setting an aggressive goal
About two years ago, management at the company set an aggressive goal to build a new development team in Solna, Sweden. They wanted a unique blend of skills and experience and engaged Sunrise Chase to be their trusted recruitment partner to ensure they would get the best talent available in such a small skill short market. They were looking for leader with 10 years of experience, at least 5 of which are leading teams of up to 20 people. Core skills were needed in basic languages such as Java with knowledge of the Agile environment. The system is combined hardware and software. The software team would be co-located with the existing hardware team. The initial team would be a staff of about six people, growing to 15-20 in 18-24 months.
On September 6, 2016 Cepheid agreed to be acquired by Danaher Corp. The acquisition was completed on November 4, 2016.
For more information
Sunrise Chase Financing can help you acquire the recruitment and executive search capabilities that your business needs in the most cost-effective and strategic way possible.
We’ll partner with credit qualified clients to customise a financing solution to suit your business and development goals, enable effective cash management, and improve your total cost of ownership.
If you are looking to recruit top talent for your organisation, please reach out to us here. One of our specialist consultants will contact you directly to discuss your business needs in more detail.